Resolute Onyx™ RONYX45022UXRecalls & reported problems
Medtronic, Inc. · STENT RONYX45022UX RESOLUTE ONYX 4.50X22 · Class 3 · Implant
All models of Resolute Onyx (101)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 5
- Deaths reported
- 1
- Injuries reported
- 4
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 5 adverse event reports that list this exact device (DI 00643169557260), received between Sep 28, 2017 and Jun 1, 2021 — classified as 1 death, 4 injuries.
The most frequently reported specific device problem is “Burst Container or Vessel” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem4
- Burst Container or Vessel1
- Difficult or Delayed Positioning1
Patient problems
- Myocardial Infarction2
- Obstruction/Occlusion1
- Occlusion1
- Patient Problem/Medical Problem1
- Renal Failure1
- Unspecified Tissue Injury1
Recent adverse event reports
The 5 most recent of 5 reports, in the reporter's own words as published by the FDA.
DeathJun 1, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
DURING THE INDEX PROCEDURE ONE RESOLUTE ONYX DES WAS IMPLANTED IN THE RCA. APPROXIMATELY 18 MONTHS POST PROCEDURE PATIENT SUFFERED KIDNEY FAILURE, PATIENT WAS PLACED ON HOSPICE AT HOME AND DIED ON THE SAME DAY. CEC ADJUDICATED THE EVENT AS CARDIAC DEATH.
Patient problems: Renal Failure
MAUDE report 11911504 ↗InjuryFeb 1, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
DURING THE INDEX PROCEDURE, THREE RESOLUTE ONYX DES WERE IMPLANTED IN THE CX. DURING A STAGED PROCEDURE, ONE RESOLUTE ONYX WAS IMPLANTED IN THE R-PDA. APPROXIMATELY 23 MONTHS POST INDEX PROCEDURE AND 22 MONTHS POST STAGED PROCEDURE, PATIENT SUFFERED FROM CHRONIC TOTAL ARTERY OCCLUSION. EVENT WAS TREATED WITH PERCUTANEOUS INTERVENTION. SAFETY ASSESSED THAT THE EVENT WAS POSSIBLY RELATED TO INDEX DEVICE, BUT NOT RELATED TO ANTIPLATELETS MEDICATION. PATIENT RECOVERED.
Patient problems: Obstruction/Occlusion; Unspecified Tissue Injury
MAUDE report 11257250 ↗InjuryAug 25, 2020Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
DURING THE INDEX PROCEDURE ONE RESOLUTE ONYX STENT WAS IMPLANTED. ONE DAY POST INDEX PROCEDURE THE PATIENT SUFFERED A NON-Q WAVE MI. THE PATIENT WAS NOT TREATED WITH ANY MEDICAL INTERVENTION. THERE WAS NO IMPACT ON THE PATIENT. THE INVESTIGATOR AND THE SPONSOR ASSESSED THE EVENT AS NOT RELATED TO PRODUCT, THERAPY OR PROCEDURE. THE CEC ASSESSED THE EVENT AS NOT RELATED, TO PRODUCT, THERAPY OR PROCEDURE.
Patient problems: Myocardial Infarction
MAUDE report 10447049 ↗InjuryNov 27, 2018Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
DURING THE INDEX PROCEDURE, ONE RESOLUTE ONYX RX WAS IMPLANTED IN THE RCA. ON THE SAME DAY, PLAQUE PROLAPSE DURING STENT PROCEDURE WAS REPORTED IN THE TARGET VESSEL. THE PATIENT WAS TREATED WITH MEDICATION. THE INVESTIGATOR ASSESSED THE EVENT AS CASUALLY RELATED TO THE DEVICE AND NOT RELATED TO THE ANTIPLATELET MEDICATION. THE PATIENT RECOVERED.
Patient problems: Myocardial Infarction; Occlusion
MAUDE report 8105355 ↗InjurySep 28, 2017Burst Container or Vessel; Difficult or Delayed Positioning; Burst Container or Vessel; Difficult or Delayed Positioning
IT WAS REPORTED THAT THE PATIENT HAD PREVIOUS STENTS. THE PHYSICIAN INTENDED TO USE A RESOLUTE ONYX DRUG ELUTING STENT TO TREAT A MILDLY TORTUOUS, MODERATELY CALCIFIED LESION WITH 80% STENOSIS IN THE PROXIMAL RIGHT CORONARY ARTERY. THERE WAS NO DAMAGE NOTED TO PACKAGING. THERE WERE NO ISSUES WHEN REMOVING THE DEVICE FROM THE HOOP. THE DEVICE WAS INSPECTED WITH NO ISSUES. NEGATIVE PREP WAS PERFORMED WITH NO ISSUES. THE LESION WAS PRE-DILATED. INFLATION DIFFICULTIES WERE REPORTED AND THE BALLOON BURST DURING STENT DEPLOYMENT AFTER 6ATM OF PRESSURE WAS APPLIED. THE STENT WAS NOT FULLY EXPANDED AND WAS SUBSEQUENTLY DEPLOYED USING TWO NON-MDT BALLOONS. THE DEVICE WAS NOT MOVED OR RE-POSITIONED IN THE LESION PRIOR TO THE BURST. THE BURST OCCURRED ON THE FIRST INFLATION OF THE DEVICE AND THERE WAS A SUDDEN DROP IN PRESSURE. THE DEVICE PASSED THROUGH A PREVIOUSLY-DEPLOYED STENT. RESISTANCE WAS NOT ENCOUNTERED WHEN ADVANCING THE DEVICE. EXCESSIVE FORCE WAS NOT USED DURING DELIVERY. THE DEVICE WAS IMPLANTED AND REMAINS IN THE PATIENT. THE PATIENT IS ALIVE AND THERE IS NO PATIENT INJURY REPORTED POST PROCEDURE.
Patient problems: Patient Problem/Medical Problem
MAUDE report 6900617 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page